110¦~10¤ë¥÷³Ì·s°T®§(¤½§i¡B¬F¥O«Å¾É¡BÃÄ«~¦^¦¬)
 

¦¬¤å¦r¸¹

¨Ó¤å¾÷Ãö

¨Ó¤å¤é´Á

¨Ó¤å¦r¸¹

¨Æ¥Ñ

1100488

½Ã¥ÍºÖ§Q³¡­¹«~ÃĪ«ºÞ²z¸p

110/10/01

FDAÃĦr²Ä1100029877¸¹

¦³Ãö¶Q¤½¥qÃÄ«~¡u´_Àuª`®g¾¯¡AHulio Solution for Injection (½Ã³¡µß¬Ì¿é¦r²Ä001149¸¹¡^¡v¥Ó½Ð½Õ¾ã¡uÃÄ«~©w´Á¦w¥þ©Ê³ø§i®æ¦¡¤ÎÀË°e®Éµ{¡v¤@®×¡A´_¦p»¡©ú¬q¡A½Ð¬d·Ó¡C

1100490

½Ã¥ÍºÖ§Q³¡­¹«~ÃĪ«ºÞ²z¸p

110/09/30

FDAÃĦr²Ä1106027333¸¹

¦³Ãö¶Q¤½¥qÃÄ«~¡u´Á¼Ö¿õ 50²@§J¡AQinlock Tablet 50mg (½Ã³¡ÃÄ¿é¦r²Ä028106¸¹¡^¡v¥Ó½Ð½Õ¾ã¡uÃÄ«~©w´Á¦w¥þ©Ê³ø§i®æ¦¡¤ÎÀË°e®Éµ{¡v¤@®×¡A´_¦p»¡©ú¬q¡A½Ð¬d·Ó¡C

1100491

½Ã¥ÍºÖ§Q³¡­¹«~ÃĪ«ºÞ²z¸p

110/10/01

FDAÃĦr²Ä1106027324¸¹

¦³Ãö¶Q¤½¥qÃÄ«~¡u"¦Ê¯S"¼Ú¥ß¬üN12E¿éª`¨Å²G¡AOlimel N12E emulsion for infusion (½Ã³¡ÃÄ¿é¦r²Ä028121¸¹¡^¡v¤Î¡u"¦Ê¯S"¨K¥ß¬üN4E¿éª`¨Å²G¡APeriOlimel N4E emulsion for infusion (½Ã³¡ÃÄ¿é¦r²Ä028122¸¹¡^¡v¥Ó½Ð½Õ¾ã¡uÃÄ«~©w´Á¦w¥þ©Ê³ø§i®æ¦¡¤ÎÀË°e®Éµ{¡v¤@®×¡A´_¦p»¡©ú¬q¡A½Ð¬d·Ó¡C

1100492

½Ã¥ÍºÖ§Q³¡

110/09/30

½Ã±Â­¹¦r²Ä1101107190¸¹

ÀË°e­×­q¤§½Ã¥ÍºÖ§Q³¡ÃÄ«~Àu¨}»s³yÃÒ©ú®Ñ¡B­^¤åGMPÃÒ©ú®Ñ¡B¿é¼Ú­ì®ÆÃĮѭ±ÃÒ©ú¤Î­^¤åGDPÃÒ©ú®Ñ¤§¥Ó½Ð¶·ª¾(§t¥Ó½Ðªí¤Î¨äªþªí)¦@4¥÷¡A½Ð´f¤©Âા©ÒÄÝ·|­û¡A½Ð¬d·Ó¡C

1100493

»O¥_¥«¬F©²½Ã¥Í§½

110/09/30

¥_¥«½Ã½]¦r²Ä11030129401¸¹

¶Q¤½¥q¥Ó½ÐÃÄ°Óµn°O¨Æ¶µÅܧó¡]Àç·~¶µ¥Ø¡G¦èÃħåµo¤Î¹s°â¡^¤@®×¡A¸g®Ö²Å¦X³W©w¡A­ã¤©Åܧóµn°O¡A½Ð¬d·Ó¡C

1100494

»O¥_¥«¬F©²½Ã¥Í§½

110/10/01

¥_¥«½Ã½]¦r²Ä1103014492¸¹

§ó¥¿¥»§½110¦~9¤ë30¤é¥_¥«½Ã½]¦r²Ä11030144851¸¹¨ç®Öµo¤§³c½æ·~ÃÄ°Ó³\¥i°õ·Ó°O¨Æ¤º®e¡A½Ð¬d·Ó¡C

1100498

½Ã¥ÍºÖ§Q³¡

110/09/30

½Ã±Â­¹¦r²Ä1101610088¸¹

¡uÂåÀø¾¹§÷§K¤©¥Z¸ü¦³®Ä´Á¶¡©Î«O¦s´Á­­«~¶µ¡vµ¥10¶µ¤½§i¡A·~¸g¥»³¡©ó¤¤µØ¥Á°ê110¦~9¤ë30¤é¥H½Ã±Â­¹¦r²Ä1101610086¸¹¤½§i¹w§i¼o¤î¡A½Ð¬d·Ó¨ÃÂા©ÒÄÝ¡C

1100499

½Ã¥ÍºÖ§Q³¡

110/09/30

½Ã±Â­¹¦r²Ä1101609771¸¹

¡uÂåÀø¾¹§÷ºÞ²z¿ìªk¡v¡B¡uÂåÀø¾¹§÷¬dÅçµn°O¼f¬d·Ç«h¡v¡B¡uÂåÀø¾¹§÷¬dÅçµn°O¤Î¼s§i¼f¬d¶O¦¬¶O¼Ð·Ç¡v·~¸g¥»³¡©ó¤¤µØ¥Á°ê110¦~9¤ë30¤é¥H½Ã±Â­¹¦r²Ä1101609769¸¹¤½§i¹w§i¼o¤î¡A½Ð¬d·Ó¨ÃÂા©ÒÄÝ¡C

1100502

»O¥_¥«¬F©²½Ã¥Í§½

110/10/04

¥_¥«½Ã­¹ÃĦr²Ä1103162318¸¹

Âા¡uÂåÀø¾¹§÷§åµo¹s°â·~­Ó¤H¸ê®ÆÀɮצw¥þºûÅ@­pµe¹ê¬I¿ìªk¡v­q©w¯ó®×¡A·~¸g½Ã¥ÍºÖ§Q³¡110¦~9¤ë29¤é½Ã±Â­¹¦r²Ä1101608678¸¹¤½§i²Ä¤G¦¸¹w§i¡A½Ð¬d·Ó¨ÃÂા©ÒÄÝ¡C

1100503

»O¥_¥«¬F©²½Ã¥Í§½

110/10/04

¥_¥«½Ã­¹ÃĦr²Ä11031624722¸¹

¦³Ãö·s¥[©Y°Ó¬ü¯Ç¨½¥§ÂåÃĦ³­­¤½¥q¥xÆW¤À¤½¥q©e°U¼Ú©¬¥Í§ÞÂåÃĪѥ÷¦³­­¤½¥q»s³y¤§¡u¬ü©w¶©¿}¦ç¿õ60¤½µ·¡]·Í¤Æ/Ôr´µ¨f©ú¡^¡]½Ã¸pÃÄ»s¦r²Ä 036008¸¹¡^¡v¡]¥þ§å¸¹¡^²£«~¦^¦¬¤@®×¡A¸Ô¦p»¡©ú¬q¡A½Ð¬d·Ó¡C

1100504

»O¥_¥«¬F©²½Ã¥Í§½

110/10/04

¥_¥«½Ã­¹ÃĦr²Ä1103066151¸¹

¶Q¤½¥q¡]¥Ã¼w¥ÍÂåªÑ¥÷¦³­­¤½¥q¡^¥Ó½Ð³c½æ·~ÃÄ°Ó¡]Àç·~¶µ¥Ø¡G¦èÃÄ¡^°±·~¤@®×¡A­ã¤©©Ò½Ð¡A´_½Ð¬d·Ó¡C

1100506

»O¥_¥«¬F©²½Ã¥Í§½

110/10/06

¥_¥«½Ã­¹ÃĦr²Ä1103163905¸¹

¦³Ãö¤Q¥þ¹ê·~ªÑ¥÷¦³­­¤½¥q¦^¦¬¡u"¤Q¥þ"¼ÄÀ£Ã­½¤¦ç¿õ80²@§J(½Ã³¡ÃÄ»s¦r²Ä058064¸¹)¡v(§å¸¹12652)ÃÄ«~¤@®×¡A´f½ÐÂા©ÒÄÝ·|­ûª¾±x¡A½Ð¬d·Ó¡C

1100507

»O¥_¥«¬F©²½Ã¥Í§½

110/10/06

¥_¥«½Ã­¹ÃĦr²Ä1103163912¸¹

¦³Ãö¥Í¹F¤Æ¾Ç»sÃĪѥ÷¦³­­¤½¥q¦^¦¬¡u"¥Í¹F"À£¥ß¦w½¤¦ç¿õ150²@§J Aprotan F.C. Tab. 150mg "Standard"(½Ã¸pÃÄ»s¦r²Ä 057178¸¹)¡v(§å¸¹TA410016¡BTA410017)ÃÄ«~¤@®×¡A´f½ÐÂા©ÒÄÝ·|­ûª¾±x¡A½Ð¬d·Ó¡C

1100508

»O¥_¥«¬F©²½Ã¥Í§½

110/10/06

¥_¥«½Ã­¹ÃĦr²Ä1103163915¸¹

¦³Ãö¥Ã³ÓÃÄ«~¤u·~ªÑ¥÷¦³­­¤½¥q¦^¦¬¡u¦w¨Kí½¤¦ç¿õ5/160²@§J(½Ã³¡ÃÄ»s¦r ²Ä060457¸¹)¡v(§å¸¹S0706001¡BS0706102¡BS0706203¡BS0803904¡BS0906805¡BS0906906¡BS0907007¡BS0907108¡BS0907209¡BS0907310¡BS0907411¡BS0907512¡BS1200513¡A¦@13§å)ÃÄ«~¤@®×¡A´f½ÐÂા©ÒÄÝ·|­ûª¾±x¡A½Ð¬d·Ó¡C

1100509

»O¥_¥«¬F©²½Ã¥Í§½

110/10/06

¥_¥«½Ã­¹ÃĦr²Ä1103163911¸¹

¦³Ãö·ç¤hÃļtªÑ¥÷¦³­­¤½¥q¦^¦¬¡u·ç¯ß§Q½¤¦ç¿õ80²@§J(½Ã¸pÃÄ»s¦r²Ä 057909¸¹)¡v(§å¸¹RTLA38¡BRTLA50-RTLA55¡A¦@7§å)¤Î¡u·ç¯ß§Q½¤¦ç¿õ160²@§J(½Ã³¡ÃÄ»s¦r²Ä059196¸¹)¡v(§å¸¹ RTHA01¡BRTHA02¡BRTHA03¡A¦@3§å)ÃÄ«~¤@®×¡A´f½ÐÂા©ÒÄÝ·|­ûª¾±x¡A½Ð¬d·Ó¡C

1100510

»O¥_¥«¬F©²½Ã¥Í§½

110/10/06

¥_¥«½Ã­¹ÃĦr²Ä1103163914¸¹

¦³Ãö¥Ã«HÃÄ«~¤u·~ªÑ¥÷¦³­­¤½¥q¦^¦¬¡u"¥Ã«H"¼Ö³t­°½¤¦ç¿õ80²@§J(½Ã¸pÃÄ»s¦r²Ä057381¸¹)¡v(§å¸¹VNT8 M001¡BVNT8 M002¡BVNT8 M003¡BVNT8 M004¡A¦@4§å)¤Î¡u"¥Ã«H"¼Ö³t­°½¤¦ç¿õ160²@§J(½Ã¸pÃÄ»s¦r²Ä057380¸¹)¡v(§å¸¹VNT16 M001¡BVNT16 M002¡BVNT16 M003¡A¦@3§å)ÃÄ«~¤@®×¡A´f½ÐÂા©ÒÄÝ·|­ûª¾±x¡A½Ð¬d·Ó¡C

1100511

»O¥_¥«¬F©²½Ã¥Í§½

110/10/07

¥_¥«½Ã­¹ÃĦr²Ä1103066726¸¹

¶Q¤½¥q¡]§»©þ°ê»Ú¦³­­¤½¥q¡^¥Ó½Ð³c½æ·~ÃÄ°Ó¡]Àç·~¶µ¥Ø¡G¦èÃÄ¡^¡BÂåÀø¾¹§÷°Ó¡]Àç·~²Ó¶µ¥Ø¡G§åµo¡B¹s°â¡^°±·~¤@®×¡A­ã¤©©Ò½Ð¡A´_½Ð¬d·Ó¡C

1100512

½Ã¥ÍºÖ§Q³¡

110/10/07

½Ã±Â­¹¦r²Ä1101409992B¸¹

¡u¤HÃþ²Ó­M¤Î°ò¦]ªvÀø»s¾¯®½Ãت̪¾±¡¦P·N°ò·Ç¡v·~¸g¥»³¡©ó110¦~10¤ë7¤é½Ã±Â­¹¦r²Ä1101409992¸¹¤½§i¡A½Ð¬d·Ó¨ÃÂા©ÒÄÝ·|­û¡C

1100514

»O¥_¥«¬F©²ªÀ·|§½

110/10/08

¥_¥«ªÀ¹Î¦r²Ä1103138338¸¹

¶Q·|¨ç³ø²Ä19©¡²Ä8¦¸²z¨Æ·|ijº[²Ä19©¡²Ä13¦¸ºÊ¨Æ·|ij¬ö¿ý®×¡A½Ð¬d·Ó¡C

1100515

»O¥_¥«¬F©²½Ã¥Í§½

110/10/08

¥_¥«½Ã­¹ÃĦr²Ä11031639042¸¹

¦³Ãö¼üºÓ¥Í§ÞÂåÃĪѥ÷¦³­­¤½¥q¸g¾P³c°â¤§¡u§J»eí½¤¦ç¿õ160²@§J¡]½Ã³¡ÃÄ»s¦r²Ä058090¸¹¡^¡v¡]§å¸¹¡G200807¡B200860¡B200861¡^ÃÄ«~¦^¦¬¤@®×¡A½Ð¨Ì»¡©ú¬q¿ì²z¡A½Ð¬d·Ó¡C

1100517

»O¥_¥«¬F©²½Ã¥Í§½

110/10/12

¥_¥«½Ã­¹ÃĦr²Ä1100140865¸¹

¦³ÃöºÞ¨îÃÄ«~ºÞ²z±ø¨Ò²Ä3±ø²Ä2¶µ³W©wÀ³¦æ¤½§i¤§¡uºÞ¨îÃÄ «~¤À¯Å¤Î«~¶µ¡v³¡¤À¤À¯Å¤Î«~¶µ¡A·~¸g¦æ¬F°|©ó¤¤µØ¥Á°ê110¦~10¤ë8¤é¥H°|»O½Ã¦r²Ä1100031413¸¹¤½§i­×¥¿¡A¨Ã¦Û§Y¤é¥Í®Ä¡A½Ð¬d·Ó¨ÃÂા©ÒÄÝ¡C

1100518

»O¥_¥«¬F©²½Ã¥Í§½

110/10/12

¥_¥«½Ã­¹ÃĦr²Ä1103067342¸¹

¶Q¤½¥q¡]°ê»Ú«ÂªL¥Í¤Æ¬ì§ÞªÑ¥÷¦³­­¤½¥q¡^¥Ó½Ð³c½æ·~ÃÄ°Ó¡]Àç·~¶µ¥Ø¡G¦èÃÄ¡^¡BÂåÀø¾¹§÷°ÓÄ~Äò°±·~¤@®×¡A­ã¤©©Ò½Ð¡A´_½Ð¬d·Ó¡C

1100519

½Ã¥ÍºÖ§Q³¡­¹«~ÃĪ«ºÞ²z¸p

110/10/14

FDAÃĦr²Ä1106026146¸¹

¦³Ãö¶Q¤½¥qÃÄ«~¡u"¬ü­}¤å"²M³Ð¾®½¦ÃÄ¡ANexoBrid Powder and gel for gel (½Ã³¡ÃÄ¿é¦r²Ä028069¸¹¡^¡v¥Ó½Ð½Õ¾ã¡uÃÄ«~©w´Á¦w¥þ©Ê³ø§i®æ¦¡¤ÎÀË°e®Éµ{¡v¤@®×¡A´_¦p»¡©ú¬q¡A½Ð¬d·Ó¡C

1100520

»O¥_¥«¬F©²½Ã¥Í§½

110/10/14

¥_¥«½Ã­¹ÃĦr²Ä1103067893¸¹

ÂાªÀ¹Îªk¤H¤¤µØ¥Á°ê¾Ç¦WÃĨó·|­ì©w5¤ëÁ|¿ì¤§ÃÄ«~Àu¨}¹B¾P³W½d(GDP)¥DÃD½×¾Â¡u«~½è¨t²ÎºÞ²z¡v¡A¦]¬Ì±¡¼vÅT©µ´Á¦Ü110¦~11¤ë11¤é(¥_°Ï)¡B15¤é(¤¤°Ï)¤Î19¤é(«n°Ï)Á|¿ì¡A½Ð¨ó§UÂા©ÒÄÝ·|­û¡A½Ð¬d·Ó¡C

1100522

½Ã¥ÍºÖ§Q³¡­¹«~ÃĪ«ºÞ²z¸p

110/10/15

FDAÃĦr²Ä1101410418¸¹

ICH M7(R2)«ü¤Þ¤Î¸É½g¯ó®×¶i¤J¤½¶}¿Ô¸ß¶¥¬q¡A½Ð¨ó§UÂા©ÒÄÝ¡A·J¾ã¸Ó«ü¤Þ¦³Ãö«Øij¨Ã½Ð©ó111¦~1¤ë31¤é«e´f´_¡A½Ð¬d·Ó¡C

1100523

»O¥_¥«¬F©²½Ã¥Í§½

110/10/13

¥_¥«½Ã­¹ÃĦr²Ä1103164665¸¹

Âા½Ã¥ÍºÖ§Q³¡­¹«~ÃĪ«ºÞ²z¸p»¡©ú¦³Ãö¿é¤JÂåÀø¾¹§÷²£«~©ó°ê¤º¶i¦æ¤¤¤å¶K¼Ð§@·~¡AÀ³¨ú±oÂåÀø¾¹§÷»s³y³\¥i³¡¤À¡A¸Ô¦p»¡©ú¬q¡A½Ð¬d·Ó¡C

1100525

½Ã¥ÍºÖ§Q³¡­¹«~ÃĪ«ºÞ²z¸p

110/10/18

FDAÃĦr²Ä1101407675¸¹

¦³Ãö¹w§i¡uICH Q6B:¥Íª«§Þ³N¡þ¥Íª«»s¾¯ÀËÅçµ{§Ç»P¤¹¦¬¼Ð·Ç¤§³W®æ­n¨D(¯ó®×)(Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products)¡v¤@®×¡A½Ð¦Ü¥»¸pºô¯¸(ºô§}¡Ghttp://www.fda.gov.tw/)¤§¡u¤½§i¸ê°T¡vºô­¶¤U¸ü¡A­Õ¹ï¤º®e¦³¥ô¦ó·N¨£©Î­×¥¿«ØijªÌ¡A½Ð·J¾ã«ü¤Þ¬ÛÃö«Øij«á©óµo¤å¦¸¤é°_60¤é¤º´f´_¡A½Ð¬d·Ó¡C

1100526

½Ã¥ÍºÖ§Q³¡­¹«~ÃĪ«ºÞ²z¸p

110/10/18

FDAÃĦr²Ä1101407668¸¹

¦³Ãö¡uICH Q5B¡G¥Íª«§Þ³N²£«~«~½è: ¥Î©ó¥Í²£­«²ÕDNA(r-DNA)­l¥Í³J¥Õ½è²£«~¤§²Ó­M¤ºªí²{ºc¿vÅ餧¤ÀªR«ü¤Þ(Quality Of Biotechnological Products: Analysis Of The Expression Construct In Cells Used For Production Of r-DNA Derived Protein Products)¡v¹w§i¯ó®×¡A½ÐÂા©ÒÄݨôf¥Ü¨ô¨£¡A½Ð¬d·Ó¡C

1100528

»O¥_¥«¬F©²½Ã¥Í§½

110/10/14

¥_¥«½Ã­¹ÃĦr²Ä11030642812¸¹

¥»§½­q©ó110¦~11¤ë23¤é(¬P´Á¤G)¤Î11¤ë25¤é(¬P´Á¥|)4³õ¦¸¡u110¦~«×¤ÆùÛ«~·~ªÌÁ¿²ß¡v¡A·qÁܶQ¤½¥q(¦æ¸¹)³ø¦W°Ñ¥[¡A½Ð¬d·Ó¡C

1100531

»O¥_¥«¬F©²½Ã¥Í§½

110/10/19

¥_¥«½Ã­¹ÃĦr²Ä1103166637¸¹

¦³Ãö¶Ôµo¯S®í®ðÅéªÑ¥÷¦³­­¤½¥q¦^¦¬¡u¶ÔµoÂå¥Î²GºA®ñ®ð¡]½Ã¸pÃÄ»s¦r²Ä 058760¸¹¡^¡v¡]§å¸¹¡GL21100410~L21100429¤Î21100501~L21100510¡A¦@30§å¡^ÃÄ«~¤@®×¡A½ÐÂા©ÒÄÝ·|­ûª¾±x¡A½Ð¬d·Ó¡C

1100532

»O¥_¥«¬F©²½Ã¥Í§½

110/10/19

¥_¥«½Ã­¹ÃĦr²Ä11031666102¸¹

¦³Ãö¤jªk¶T©öªÑ¥÷¦³­­¤½¥q¸g¾P³c°â¤§¡uº~¥ÍµÑºZ­GÁû²É(½Ã¸pÃÄ¿é¦r²Ä 025180¸¹)¡v(§å¸¹AIZA¡BAIZB¡BLMZA¡BLMZB)ÃÄ«~¦^¦¬¤@®×¡A½Ð¨Ì»¡©ú¬q¿ì²z¡A½Ð¬d·Ó¡C

1100533

½Ã¥ÍºÖ§Q³¡­¹«~ÃĪ«ºÞ²z¸p

110/10/19

FDAÃĦr²Ä1101410448¸¹

¥»¸p­q©ó110¦~10¤ë29¤é(¬P´Á¤­)¤U¤È1®É30¤À¦Ü4®É¡A°²±iºaµo°òª÷·|°ê»Ú·|ij¤¤¤ß 1001·|ijÆUÁ|¿ì¡uÃÄ«~¬dÅçµn°O¼f¬dº[½u¤W¥Ó½Ð§@·~¥­¥x(ExPRESS)·~ªÌ»¡©ú·|¡v¡A½Ð¶Q·|Âા©ÒÄÝ·|­û¿ãÅD³ø¦W°Ñ¥[¡C

1100534

»O¥_¥«¬F©²½Ã¥Í§½

110/10/19

¥_¥«½Ã­¹ÃĦr²Ä1103167159¸¹

Âા¡u©Ó¯²¤½¦³©Î°êÀç¨Æ·~¤g¦aºØ´Ó¤¤ÃÄÃĥδӪ«¼úÀy¤Î¯²¸î´Á­­«O»Ù¿ìªk¡v¡A·~¸g½Ã¥ÍºÖ§Q³¡©ó¤¤µØ¥Á°ê110¦~10¤ë18¤é¥H½Ã³¡¤¤¦r²Ä1101861315¸¹¥O­q©wµo¥¬¡AÀË°eµo¥¬¥O¼v¥»¡]§tªþ¥ó¡^¡BÁ`»¡©ú¤Î³v±ø»¡©ú¦U1¥÷¡A½Ð¬d·Ó¨ÃÂા©ÒÄÝ¡C

1100535

½Ã¥ÍºÖ§Q³¡­¹«~ÃĪ«ºÞ²z¸p

110/10/19

FDA¾¹¦r²Ä1101611316¸¹

¡u°©ÅèµÄ¤º©T©w¸Ë¸m¡v¡B¡u¤ú¬ì¥Î³³²¡§÷®Æ¡v¤Î¡u¿é²GÀ°®ú¡vµ¥3¶µÁ{§É«e´ú¸Õ°ò·Ç¡A·~¸g¥»¸p©ó110¦~10¤ë19¤é¥HFDA¾¹¦r²Ä1101611315¸¹¤½§i¡A½Ð¬d·Ó¨ÃÂા©ÒÄÝ¡C

1100536

½Ã¥ÍºÖ§Q³¡

110/10/13

½Ã±Â­¹¦r²Ä1101606804¸¹

¡u±o¥H¹q¤l¤Æ»¡©ú®Ñ¨ú¥N¤¤¤å»¡©ú®Ñ¤§ÂåÀø¾¹§÷«~¶µ¤Î¨ä¼ÐÅÒ©Î¥]¸ËÀ³¥[µù¨Æ¶µ¡v­q©w¯ó®×¡A·~¸g¥»³¡©ó¤¤µØ¥Á°ê110¦~10¤ë13¤é¥H½Ã±Â­¹¦r²Ä1101606803¸¹¤½§i¹w§i¡A½Ð¬d·Ó¨ÃÂા©ÒÄÝ¡C

1100538

½Ã¥ÍºÖ§Q³¡­¹«~ÃĪ«ºÞ²z¸p

110/10/18

FDAÃĦr²Ä1109041955¸¹

¦³Ãö¦æ¬F°|¹A·~©e­û·|°Ê´Óª«¨¾¬ÌÀˬ̧½(¥H¤UºÙ¨¾À˧½)±N©ó110¦~10¤ë22¤é­×¥¿¡uÃ~Âå®v±M®×¥Ó½Ð¤H¥ÎÃÄ«~ªvÀø°Êª«¤§¼È¦æ´À¥N«~¶µ(²Ä¤@¦¸¤½§i)¡v¡A¸Ô¦p»¡©ú¡A½Ð¬d·Ó¨ÃÂા©ÒÄÝ·|­û¡C

1100541

»O¥_¥«¬F©²½Ã¥Í§½

110/10/21

¥_¥«½Ã­¹ÃĦr²Ä1100142076¸¹

Âા½Ã¥ÍºÖ§Q³¡­¹«~ÃĪ«ºÞ²z¸p(¤UºÙ­¹Ãĸp)­q©ó110¦~11¤ë1¤é(¬P´Á¤@)Á|¿ì¡uÂåÀø¾¹§÷°ê²£°ê¥Î«Å¾É»¡©ú·|¡v¡A½Ð¿ãÅD³ø¦W°Ñ¥[¡A¸Ô¦p»¡©ú¡A½Ð¬d·Ó¨ÃÂા©ÒÄÝ¡C

1100542

»O¥_¥«¬F©²½Ã¥Í§½

110/10/21

¥_¥«½Ã­¹ÃĦr²Ä1103167622¸¹

¦³Ãö¦æ¬F°|¹A·~©e­û·|°Ê´Óª«¨¾¬ÌÀˬ̧½(¥H¤UºÙ¨¾À˧½)±N©ó110¦~10¤ë22¤é­×¥¿¡uÃ~Âå®v±M®×¥Ó½Ð¤H¥ÎÃÄ«~ªvÀø°Êª«¤§¼È¦æ´À¥N«~¶µ(²Ä¤@¦¸¤½§i)¡v¡A¸Ô¦p»¡©ú¡A½ÐÂા©ÒÄÝ·|­ûª¾±x¡A½Ð¬d·Ó¡C

1100543

»O¥_¥«¬F©²½Ã¥Í§½

110/10/21

¥_¥«½Ã­¹ÃĦr²Ä1103167779¸¹

¦³Ãö¬R¹F¥Í§Þ¦³­­¤½¥q»s°â¤§¡u“¬R¹F”¦¨¤H/¨àµ£Âå¥Î¤f¸n(¥¼·Àµß)(½Ã³¡Âå¾¹»s³ü¦r²Ä009136¸¹¡B½Ã³¡Âå¾¹»s³ü¦r²Ä009133¸¹¡^¡B»s³y¤é´Á¡G2021.07.15¡vÂåÀø¾¹§÷¦^¦¬¤@®×¡A¸Ô¦p»¡©ú¬q¡A½Ð¬d·Ó¡C

1100544

»O¥_¥«¬F©²½Ã¥Í§½

110/10/20

¥_¥«½Ã­¹ÃĦr²Ä1103069562¸¹

¦³Ãö»O¥_¥«ÃÄ®v¤½·|©Ó±µ½Ã¥ÍºÖ³¡­¹«~ÃĪ«ºÞ²z¸p©e°U­pµe¡A­q©ó110¦~11¤ë9¤é(¬P´Á¤G)Á|¿ì¤ÆùÛ«~¤£¨}¨Æ¥ó³q³ø±Ð¨|°V½m¡A½Ð¤½·|¨ó§UÂા©ÒÄÝ·|­û¡A¨Ã¹ªÀy¿ãÅD³ø¦W°Ñ¥[¡A½Ð¬d·Ó¡C

1100551

½Ã¥ÍºÖ§Q³¡

110/10/25

½Ã±Â­¹¦r²Ä1101410981¸¹

¥»³¡¤½§i¡uICH M9¡G¨Ì¾Ú¥Íª«Ãľ¯¾Ç¤ÀÃþ¨t²Î¤§¥ÍÅé¬Ûµ¥©Ê¸ÕÅç§K°£«ü¤Þ¡v¤Î±N¥»³¡105¦~8¤ë9¤é³¡±Â­¹¦r²Ä1051406824¸¹¤½§i¡u¾Ç¦WÃÄÂåÃÄ«~·»¸Ñ«×¤Î¬ï³z©Ê¤ÀÃþ­ì«h¥H·»Â÷²v¦±½u¤ñ¹ï¸ÕÅç¨ú¥N¥ÍÅé¬Ûµ¥©Ê¸ÕÅç¥Ó½Ð«ü¤Þ¡v°±¤î¾A¥Î¤@®×¡A½Ð¦Ü¥»³¡­¹«~ÃĪ«ºÞ²z¸pºô¯¸
(http://www.fda.gov.tw/) ¤§¡u¤½§i¸ê°T¡vºô­¶¤U¸ü¡A½Ð¬d·Ó¨ÃÂા©ÒÄÝ·|­û¡C

1100553

¥x¥_¥«¤¤ÃÄ°Ó·~¦P·~¤½·|

110/10/20

¥_¥«¤¤ÃĦr²Ä110044¸¹

¥»·|²Ä20©¡²Ä1¦¸·|­û¥Nªí¤j·|·~©ó¥Á°ê110¦~10¤ë15¤é¥l¶}¡A¨Ã¨Ìªk¿ï¥X²Ä20©¡²zºÊ¨Æ¡C­Z·£©Ó»X¦P·~¥Nªí«p·R¡AÂÍÁp¥»·|²Ä20©¡²z¨Æªø¡A§Y¤é±µ½fµø¨Æ¡A¤µ«á¥²ºÉ¥þ¤O±À®i·|°È¡A·q¬è®É½ç±Ð¨¥¡A¦J¤£¶e¡A½Ð¬d·Ó¡C

1100554

°]¹Îªk¤H¤u·~§Þ³N¬ã¨s°|

110/10/26

¤u¬ã¶q¦r²Ä1100021821¸¹

·qÁÜ°Ñ¥[110¦~«×­¹«~ÃĪ«ºÞ²z¸p¡uÂåÀø¾¹§÷«~½èºÞ²z¨t²Î·Ç«h±MÃD¨t¦C¡v°V½m½Òµ{¡A½Ð ¬d·Ó¡C

1100555

½Ã¥ÍºÖ§Q³¡­¹«~ÃĪ«ºÞ²z¸p

110/10/26

FDAÃĦr²Ä1101410667B¸¹

¦³Ãö¤½§i¡uICH Q3A(R2)¤ÎQ3B(R2)¡G·sÃĤ§¤£¯Âª««ü¤Þ(Impurities in New Drug Substances and New Drug Products)¡v¤@®×¡A½Ð¦Ü¥»¸pºô¯¸http://www.fda.gov.tw/) ¤§¡u¤½§i¸ê°T¡vºô­¶¤U¸ü¡A½Ð¬d·Ó¨ÃÂા©ÒÄÝ·|
­û¡C

1100556

»O¥_¥«¬F©²½Ã¥Í§½

110/10/26

¥_¥«½Ã­¹ÃĦr²Ä1103167656¸¹

¦³Ãö¦æ¬F°|©ó110¦~10¤ë8¤é¤½§i­×¥¿¡uºÞ¨îÃÄ«~¤À¯Å¤Î«~¶µ¡v³¡¤À¤À¯Å¤Î«~¶µ¡A¨Ã¦Û110¦~10¤ë8¤é¥Í®Ä¡A½Ð¬d·Ó¨ÃÂા©ÒÄÝ¡C

1100557

½Ã¥ÍºÖ§Q³¡­¹«~ÃĪ«ºÞ²z¸p

110/10/27

FDA¾¹¦r²Ä1101611877¸¹

¦³Ãö¥»¸p¤½§i­q©w¡u¬y·P¯f¬r§Ü­ì§Ö¿zÀË´ú¨t²Î§Þ³N°ò·Ç¡v¤Î¡uÅé¥~¶EÂ_ÂåÀø¾¹§÷¦w©w©Êµû¦ô§Þ³N°ò·Ç¡v2¶µÂåÀø¾¹§÷§Þ³N°ò·Ç¡A´f½Ð¶Q·|Âા©ÒÄÝ·|­û¡A½Ð¬d·Ó¡C

1100558

»O¥_¥«¬F©²½Ã¥Í§½

110/10/27

¥_¥«½Ã­¹ÃĦr²Ä1103168805¸¹

¡uÃÄ«~Àu¨}½Õ¾¯§@·~·Ç«h¡v­×¥¿¯ó®×¡A·~¸g½Ã¥ÍºÖ§Q³¡©ó¤¤µØ¥Á°ê110¦~10¤ë21¤é¥H½Ã±Â­¹¦r²Ä1101409214¸¹¤½§i¹w§i¡A½Ð´f¤©Âા©ÒÄÝ·|­ûª¾±x¡A½Ð¬d·Ó¡C

1100559

»O¥_¥«¬F©²½Ã¥Í§½

110/10/27

¥_¥«½Ã­¹ÃĦr²Ä1103169064¸¹

¦³Ãö°ö¤OÃÄ«~¤u·~ªÑ¥÷¦³­­¤½¥q¦^¦¬¡u“°ö¤O”´¶Ã¹¶t¿õ667²@§J ¡]¾L»Ä¶t¡^(½Ã¸pÃÄ»s¦r²Ä036794¸¹)¡v(§å¸¹020068¡B 020070¡B020074¡B020077¡B020081¡B020086¡B021001¡B 021005¡B021010¡B021013¡B021014¡B021017¡B021022¡B 021024¡B021028¡B021033¡B021034¤Î021039¡A
¦@18§å)ÃÄ«~¤@®×¡A½Ð´f¤©Âા©ÒÄÝ·|­ûª¾±x¡A½Ð¬d·Ó¡C

1100560

°]¹Îªk¤HÃÄ®`±ÏÀÙ°òª÷·|

110/10/27

ÃÄÀÙ¥ø¦r²Ä1103000074¸¹

¥»·|±N©ó110¦~11¤ë29¤éÁ|¿ì¡u110¦~«×ÂåÀø¾¹§÷¤W¥««á¤lªk³W¤Î¨t²Î»¡©ú·|¡v¡A´f½ÐÂા©ÒÄݳø¦W°Ñ¥[¡A½Ð¬d·Ó¡C

1100564

½Ã¥ÍºÖ§Q³¡­¹«~ÃĪ«ºÞ²z¸p

110/10/28

FDAÃĦr²Ä1106030164¸¹

¦³Ãö¶Q¤½¥qÃÄ«~¡uÃþ§Æº¿ ¥Ö¤Uª`®g²G¡ARemsima Solution for injection (½Ã³¡µß¬Ì¿é¦r²Ä001155¸¹¡^¡v¥Ó½Ð½Õ¾ã¡uÃÄ«~©w´Á¦w¥þ©Ê³ø§i®æ¦¡¤ÎÀË°e®Éµ{¡v¤@®×¡A´_¦p»¡©ú¬q¡A½Ð¬d·Ó¡C

¡@

¡@

¡@

¡@

¡@

¡@

ºô­¶³]­p